長拓興業有限公司Chung Tuo Co.,Ltd

2019 2/21-23 CTO Seoul Camp 2019

Tue, 19 Feb 2019 06:30:00 +1600

2019 2/21-23 CTO Seoul Camp 2019

CHANGE IS HERE!! Want to know how Meril have added #MoreToLifeOnWeb?

Fri, 15 Feb 2019 06:10:00 +1600

For more update - Follow MERIL social media pages below

https://www.merillife.com/

2019 4/27 ~ 30 TCTAP Coex, Seoul Korea

Thu, 03 Jan 2019 06:20:00 +1600

24th Cardiovascular Summit TCTAP 2019

April 27 - 30, 2019

Coex, Seoul, Korea

2019, 2/28 ~ 3/3 10th India Live

Thu, 03 Jan 2019 06:00:00 +1600

AN ERA OF EMERGING TECHNOLOGY

28th Feb - 3rd Mar 2019

Renaissance Mumbai Convention Centre Hotel Powai, Mumbai

2019,1/12 ~ 13 TTT 2019 TAIWAN TRANSCATHETER THERAPEUTICS LIVE COURSE

Tue, 06 Nov 2018 09:00:00 +1600

TAIWAN TRANSCATHETER THERAPEUTICS

LIVE COURSE

JAN 12~13.2019

NTUH International Convention Center, Taipei Taiwan

長拓遷移通知

Fri, 02 Nov 2018 04:30:00 +1600

長拓興業有限公司【遷移通知】

親愛的客戶/同業先進/協力廠商鈞鑒 :

本公司為提升客戶服務品質及致力於提供同仁良好的工作環境，將公司遷移至以下新址，由於跨區域，原服務電話及傳真均有改號。

通訊地址請依下列聯絡方式更新，敬祈舊雨新知繼續支持與愛護。

【長拓興業有限公司】

電話號碼 : (02)8666-0077

傳真號碼 : (02)8666-5095

公司地址 : 23159新北市新店區安興路125之12號5樓

順頌醫祺!

2018, 11/29 ~ 12/2 海峡两岸医药卫生交流协会，心血管专业委员会第九届年会.

Fri, 02 Nov 2018 04:20:00 +1600

2018海峡两岸医药卫生交流协会，心血管专业委员会第九届年会.

http://www.cs-csf.com

2018.11.29 - 2018.12.2

中國。廈門佰翔五通酒店

Click here for more information

Credence BtK scaffold can prevent re-stenosis

Wed, 27 Jun 2018 06:29:26 +1600

Summary

Stents are the mainstay of endovascular revascularization in peripheral interventions, but metal in stents can cause re-occlusions to occur in the long run. One answer is to use a scaffold; it can act like a stent and scaffold the segment but is later resorbed, preventing re-stenosis.

Investigator Vimal Someshwar outlines 30-day findings on stent thrombosis from a study into the performance of the Credence BtK bioresorbable scaffold, a bioresorbable sirolimus-eluting stent for the intra-popliteal artery. Watch as he explains the chemistry behind the hybrid model, which consists of a closed cell at the ends and an open cell design along the shaft of the stent, and summarises the clinical criteria for inclusion in the study.

V. Someshwar sees a “bright future” for this device; learn more about the data on wound healing and target lesion revascularization, and discover what his prediction is based upon…

MeRes100 findings to feed into a large randomized trial

Wed, 27 Jun 2018 05:00:00 +1600

Summary

First-generation scaffolds were large devices 150 µm thick and had several limitations as a result; apart from being difficult to use with poor deliverability, one of their biggest deficiencies was safety, with high scaffold thrombosis rates. At EuroPCR 2018, investigator Ashok Seth presented findings on the MeRes100, the first ever bioresorbable scaffold with a strut thickness of 100 µm. He describes the “fascinating characteristics” and “unique architecture” of the scaffold and outlines the advantages conferred by its PLLA backbone with a sirolimus-eluting coating and its availability in a variety of sizes. Discover his thoughts on the 2-year clinical optimized computed tomography (OCT) and intravascular ultrasound (IVUS) first-in-human data on MeRes100 in 108 patients with coronary artery disease. The “extremely favorable” and “encouraging” results will form the basis of a pivotal 2000-patient, randomized study comparing MeRes100 to a Xience everolimus-eluting stent that is due to commence later this year. Watch to learn more…

MyVal – THV ( Is MyVal Safe at 30 days in severe aortic stenosis? Hotline EuroPCR 2018 )

Wed, 27 Jun 2018 04:30:00 +1600

Summary

Watch as investigator Rao Ravinder Singh summarises the findings from the MyVal study, which he presented at EuroPCR 2018. The first-in-man study reveals 30-day clinical and echocardiographic results of a next-generation balloon-expandable transcatheter aortic valve replacement (TAVR) system in 30 patients with severe stenosis of the native aortic valve. R.R. Singh outlines the technology of the valve, and its performance immediately post-procedure and at 30 days in relation to mean gradient, pacemaker rate, and mild, moderate, and severe paravalvular leak. Find out his conclusions on its safety in these patients…